Commentary
Video
Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC
Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research, discusses findings from the second interim overall survival (OS) analysis of the phase 3 MARIPOSA-2 study (NCT04988295) investigating amivantamab-vmjw (Rybrevant) plus chemotherapy in patients with EGFR-mutated, advanced non–small cell lung cancer who have progressed on osimertinib (Tagrisso).
Latest CME
View All
Video
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Jun 6th 2025 - Jul 12th 2025
online-activity
Video
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Jun 6th 2025 - Jul 12th 2025
online-activity
Video
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Jun 5th 2025 - Jul 12th 2025
online-activity
Related Content
